News and Announcements
SUDA Annual Update 2016; IP Filed & Major Deal Signed
- Published January 19, 2017 5:00PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
SUDA Ltd (ASX:SUD) is a drug delivery company headquartered in Perth, WA. The Company is developing low-risk oral sprays using novel formulations of existing pharmaceuticals. The many potential benefits of administering drugs through the cheeks, tongue, gums to include ease of use, lower dosage, reduced side effects and faster response time. During the year, the Company completed an array of achievements;
- Completed the development and filed IP for its novel penetration enhancing technology.
- November 2016, SUDA announced a major deal with Eddingpharm, a leading Chinese pharmaceutical company.
- SUDA’s ZolpiMistÔ oral spray for the treatment of insomnia in China. The total deal value could exceed $34 million in upfront, milestone and royalty payments.
Active discussions are ongoing with approximately 60 pharmaceutical companies.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
